# NeraCare

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neracare

- Industry: Healthcare
- Headquarters: Cologne, Germany
- Website: www.melagenix.de
- Total disclosed funding: $8.8M
- Latest round: Series A (Mar 5, 2020)
- Investors on record: 2

## About

NeraCare GmbH is a biotechnology company specializing in advanced therapeutic products focused on regenerative medicine, particularly for skin healing and tissue repair. Their innovative solutions cater to healthcare providers and clinics across Europe and North America.Founded in 2015, NeraCare GmbH operates in Cologne, Germany. The company is dedicated to developing therapeutic solutions for medical conditions, particularly in regenerative medicine. The CEO, Matthias Ackermann, leads the firm, which raised EUR 8 million in Series A funding in March 2020, backed by MIG Capital and BayBG. This funding was aimed at furthering their product development and market expansion. As of now, NeraCare has completed a total of 1 deal, with a current company valuation of EUR 24.761 mn.NeraCare specializes in innovative solutions within the biotechnology sector, focusing on the development of advanced therapeutic products aimed at addressing a range of medical conditions. The company’s core offerings include proprietary formulations designed for regenerative medicine, particularly in the areas of skin healing and tissue repair. These products are engineered to enhance healing processes, making them suitable for use in clinical settings, including hospitals and outpatient facilities. NeraCare targets a diverse customer base that includes healthcare providers, dermatology clinics, and pharmaceutical companies, primarily in the European and North American markets. The firm’s commitment to research and development ensures that its products are released with the latest scientific advancements, catering to the evolving needs of healthcare professionals and patients alike.NeraCare's revenue model is structured around direct sales and partnerships within the healthcare ecosystem, facilitating transactions between the company and its clinical clients. The company engages in B2B relationships, providing its therapeutic products to hospitals and medical facilities that utilize them in patient treatments. These transactions may involve bulk orders or subscription-based agreements where healthcare providers receive regular shipments of the products. NeraCare’s flagship offerings are positioned at competitive price points, designed to ensure accessibility while reflecting the advanced technology and research underpinning each product. This structured approach to revenue generation allows NeraCare to maintain strong relationships with its clientele while expanding its market reach.NeraCare GmbH is focused on launching new products designed for regenerative medicine, with specific emphasis on skin healing technologies. The recent EUR 8 million funding from March 2020 will support these new product developments and enhance their research capabilities. Additionally, NeraCare plans to expand into North American markets by 2023, aiming to strengthen its presence while catering to a broader customer base. This strategy is underpinned by their commitment to innovation and market responsiveness.

## Funding rounds

- Series A, Mar 5, 2020, $8.8M — BayBG, MIG Capital

## Investors

- BayBG (https://capitalatlas.ai/funds/baybg) — Series A
- MIG Capital (https://capitalatlas.ai/funds/mig-capital) — Series A